Full Press Release Details
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC.
IDYA
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
Key Takeaway: IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy R and IDE397 in MTAP Deletion NSCLC
Price reaction · baseline $21.95 (2025-02-12 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
-5.4%
day 1
-4.3%
day 3 · peak
-5.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma